Clinical Manifestations of β-Thalassemia Major in Two Different Altitudes; Bushehr and Shahrekord

نویسندگان

  • Mohammad Reza Ravanbod
  • Ali Movahed
  • Afshin Ostovar
  • Ali Hajigholami
  • Gholamreza Khamisipour
  • Shokrollah Farrokhi
  • Hossein Darabi
  • Yasaman Khosravi
  • Mohammad Kazzem Gheybi
چکیده

BACKGROUND Patients with β-thalassemia major (TM) develop iron overload through increased iron absorption and transfusional therapy and it's the most important complication of TM. Thalassemia is common in coastal regions and lands with low altitudes. The aim of this study is to determine the effect of high and low altitude on serum ferritin and treatment requirement in two groups of β-thalassemia major (TM) patients. SUBJECTS AND METHODS Patients were divided into two groups, the first group (No: 50) living at sea level (in the port of Bushehr, Iran) and the second group (No: 40) living at the altitude of 2061 m (in the city of Shahrekord, Iran). All patient's clinical history, blood transfusion and laboratory tests including complete blood count and hemoglobin electrophoresis were reviewed. RESULTS There were no significant difference in ferritin levels, transfusion period and diabetes incidence of the two cities patients (P>0.05). Patient's cardiac function and liver condition were significantly better in patients of Bushehr (P<0.05). Patients under 20 years in Bushehr were less splenectomized in comparison with Shahrekord (P<0.05). CONCLUSION Our result showed that some of clinical manifestations of patients in low altitude such as cardiac and liver condition were better. But it did not affect ferritin level probably due to transfusion and chelating therapy. Totally patients of Bushehr had better conditions and had longer survivals.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effects of Alpha-Lipoid Acid on Serum Iron, Total Iron Binding Capacity and Hematological Indices in β-Thalassemia Major Patients: A Cross Over Clinical Trial

Background and Objectives: Accumulation of iron is the most common consequences of repeated blood transfusions in β-thalassemia major patients. Iron chelating effects of alpha-lipoic acid have been reported by several studies. The aim of this study was to investigate effects of supplementation with alpha-lipoic acid, as a chelator, on serum iron and hematological indices in these patients.  Ma...

متن کامل

Quality of life among patients with beta-thalassemia major in Shahrekord city, Iran

Background and aims: Nowadays introduction of regular blood transfusion therapy has obviously improved the life expectancy of patients with thalassemia. However, these patients face with newer challenges which influence their quality of life (QoL). In this study, the aim of this study was to measure QoL among patients with β-thalassemia major (β-TM). Methods:</str...

متن کامل

The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial

Background Beta thalassemia (β-thalassemia) is one of the most common genetic disorders that reduces the amount of specific chain production in hemoglobin. The aim of this study was to compare the efficacy and safety of Desfonak with Desferal in patients with β-thalasse...

متن کامل

EVALUATION OF PULMONARY IRON OVER LOAD IN PATIENTS WITH Β-THALASSEMIA MAJOR USING SPIROMETRY

Background & Aims: Spirometry changes in thalassemic patients can be obstructive or restrictive and pulmonary dysfunction depends on age and body iron overload. In this study the effectiveness of lung spirometry in detecting iron overload in patients with β-thalassemia was investigated. Materials & Methods: This cross-sectional (descriptive-analytic) study investigated the spirometry test resu...

متن کامل

بررسی رابطه مصرف هیدروکسی اوره با سنگ های صفراوی در بیمارن بتا تالاسمی ماژور و اینترمدیا

Background and Purpose: Cholelithiasis is a common problem among patients with homozygous major and intermediate β-thalassemia due to chronic hemolysis, ineffective erythropoesis and other factors that causes variety of side effects. Hydroxyurea (HU) decreases hemolysis by increasing HbF production in homozygous β-thalassemia patients. Up to now, there have not been evidences about relationsh...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2016